Viking Therapeutics Releases Q3 2024 Financial Results and Corporate Update
Viking Therapeutics Announces Positive Financial Results and Clinical Pipeline Update Important Developments Conference call scheduled for 4:30 p.m. ET today End-of-Phase 2 Meeting for Subcutaneous VK2735 for Obesity Planned for 4Q24 Phase 2 Study of Oral VK2735 in Obesity Expected to Begin 4Q24 Results of Phase 2b VOYAGE Study of VK2809 in NASH/MASH With Fibrosis…